These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 14520526)
1. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H; Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526 [TBL] [Abstract][Full Text] [Related]
2. [Gastrointestinal cancer]. Takahashi Y Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558 [TBL] [Abstract][Full Text] [Related]
3. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer. Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459 [TBL] [Abstract][Full Text] [Related]
4. Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. Qiu MZ; Lin JZ; Wang ZQ; Wang FH; Pan ZZ; Luo HY; Li YH; Zhou ZW; He YJ; Xu RH Int J Biol Markers; 2009; 24(4):258-64. PubMed ID: 20082274 [TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. Sun Z; Zhang N World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664 [TBL] [Abstract][Full Text] [Related]
6. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Lai IR; Lee WJ; Huang MT; Lin HH Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226 [TBL] [Abstract][Full Text] [Related]
7. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer. Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer. Moriyama J; Oshima Y; Nanami T; Suzuki T; Yajima S; Shiratori F; Funahashi K; Shimada H Surg Today; 2021 Oct; 51(10):1638-1648. PubMed ID: 33682011 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of early postoperative tumor marker response in gastric cancer. Nam DH; Lee YK; Park JC; Lee H; Shin SK; Lee SK; Lee YC; Cheong JH; Hyung WJ; Noh SH; Kim CB Ann Surg Oncol; 2013 Nov; 20(12):3905-11. PubMed ID: 23807661 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Li Y; Yang Y; Lu M; Shen L Hepatogastroenterology; 2011; 58(112):2166-70. PubMed ID: 22024091 [TBL] [Abstract][Full Text] [Related]
12. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491 [TBL] [Abstract][Full Text] [Related]
13. The Changes and Clinical Significance of Preoperative and Postoperative Serum CEA and CA19-9 in Gastric Cancer. Jing R; Cui M; Ju S; Pan S Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255307 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic values of anti-helicobacter pylori antibody combined with serum CA724, CA19-9, and CEA for young patients with early gastric cancer. Gong X; Zhang H J Clin Lab Anal; 2020 Jul; 34(7):e23268. PubMed ID: 32118318 [TBL] [Abstract][Full Text] [Related]
15. [Stomach adenocarcinomas: comparison between CA 19-9 and carcinoembryonic antigen for the diagnosis of recurrences after surgical treatment]. Ychou M; Tuszinski T; Pignon JP; Bidart JM; Bellet D; Bohuon C; Rougier P Gastroenterol Clin Biol; 1992; 16(11):848-52. PubMed ID: 1483553 [TBL] [Abstract][Full Text] [Related]
16. Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer. Shibata C; Nakano T; Yasumoto A; Mitamura A; Sawada K; Ogawa H; Miura T; Ise I; Takami K; Yamamoto K; Katayose Y BMC Surg; 2022 Jun; 22(1):213. PubMed ID: 35655198 [TBL] [Abstract][Full Text] [Related]
17. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer. Yin LK; Sun XQ; Mou DZ Asian Pac J Cancer Prev; 2015; 16(9):3867-70. PubMed ID: 25987051 [TBL] [Abstract][Full Text] [Related]
18. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer. Yang XQ; Chen C; Wang FB; Peng CW; Li Y Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer. Kim HJ; Lee KW; Kim YJ; Oh DY; Kim JH; Im SA; Lee JS Acta Oncol; 2009; 48(3):385-90. PubMed ID: 18855156 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]